DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Deutsche Boerse AG 01:44:28 2024-05-30 pm EDT | ||
| 0.108 EUR | -6.90% |
|
| 1 month | -45.28% | ||
| 3 months | -64.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 0.108 | -6.90% |
| 24-05-29 | 0.116 | +3.57% |
| 24-05-28 | 0.112 | 0.00% |
| 24-05-27 | 0.112 | +14.29% |
| 24-05-24 | 0.098 | -3.92% |
Delayed Quote Deutsche Boerse AG
Last update May 30, 2024 at 01:44 pm EDT
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM37QP |
| ISIN | DE000VM37QP2 |
| Date issued | 2023-10-19 |
| Strike | 100 $ |
| Maturity | 2024-12-20 (204 Days) |
| Parity | 10 : 1 |
| Emission price | 0.62 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.88 € |
|---|---|
| Lowest since issue | 0.098 € |
| Spread | 0.01 € |
| Spread % | 8.20% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
911.5
DKK
Average target price
917.2
DKK
Spread / Average Target
+0.63%
- Stock Market
- Certificates
- Certificat
